A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Public ClinicalTrials.gov record NCT04844073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-186 (MVC-101). Participants may receive treatment throughout the study for a maximum of 13 months and will be followed up at 30 days and 90 days and then every 12 weeks for up to 48 weeks after the last treatment.
Study identification
- NCT ID
- NCT04844073
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 95 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 8, 2021 (Actual)
- Primary completion
- Jun 17, 2025 (Actual)
- Completion
- Jun 17, 2025 (Actual)
- Last update posted
- Sep 24, 2026
2021 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | San Diego | California | 92037 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| University of Colorado - Anschutz Medical Campus - PPDS | Aurora | Colorado | 80045-2517 | — |
| Yale University | New Haven | Connecticut | 06510-3206 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northwestern University | Chicago | Illinois | 60611-2814 | — |
| Indiana University | Indianapolis | Indiana | 43202 | — |
| University of Minnesota Medical Center, Fairview | Minneapolis | Minnesota | 55414-2959 | — |
| Columbia University Medical Center -161 Fort Washington | New York | New York | 10032 | — |
| Novant Health Cancer Institute - Elizabeth Head and Neck | Charlotte | North Carolina | 28204-3282 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57105-1521 | — |
| Mary Crowley Cancer Research Centers Medical City - SCRI - PPDS | Dallas | Texas | 75230 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030-4000 | — |
| Fred Hutchinson Cancer Research Center - 1100 Fairview Ave N | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04844073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2026 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04844073 live on ClinicalTrials.gov.